Key result
Placental multiomics and imaging hold potential to improve early congenital heart disease detection.
Why the study?
Current prenatal screening methods frequently miss congenital heart disease despite its high prevalence and impact, and the placenta is an underexplored diagnostic tissue linked to CHD.
Leveraging placental imaging, in vitro models, and multiomics may improve the early detection and understanding of congenital heart disease.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for placental biomarkers in CHD; requires prospective validation before clinical adoption.
Congenital heart disease ( CHD ) remains the most common birth defect and a leading contributor to global infant morbidity and mortality. Early diagnosis improves outcomes, yet current screening methods frequently miss CHD during routine prenatal screening. The placenta, which develops in parallel with the fetal heart and shares critical molecular pathways, represents an underexplored diagnostic tissue. We highlight clinical, epidemiological, and mechanistic insights that link placental abnormalities to CHD and explore how imaging, in vitro models, and multiomics can improve our understanding of the placenta-heart axis. Leveraging these tools will offer opportunities for earlier CHD detection and illuminate avenues for intervention.
No takes yet. Share an insight, caveat, or question.
Howard et al. (2026) conducted a review in Congenital heart disease (CHD). The placenta represents an underexplored diagnostic tissue for congenital heart disease, and leveraging imaging, in vitro models, and multiomics may improve early detection and intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: